*  Patent USRE41998 - Compositions and methods of treatment of sympathetically maintained pain - Google Patents
Chemical formulas for several sympatholytic agents are given. ... Topical application of the sympatholytic agent is also used in ... known collectively as sympatholytic agents. Chemical formulas for several sympatholytic agents are given. ... A suitable sympatholytic agent with alpha-1 adrenoreceptor antagonist activity may also be selected from the class of compounds ... Specifically preferred sympatholytic compounds which are not encompassed in Formulas I through XVIII from which a suitable ...
  http://www.google.com/patents/USRE41998?dq=6,034,652
*  Catecholamine-depleting Sympatholytic global drug patents, generic suppliers and generics
Generic options for Catecholamine-depleting Sympatholytic pharmaceutical drugs, including patent status, patent expiration ... Catecholamine-depleting Sympatholytic Drug-Class List. « Back to Dashboard. No matches for this query. « Back to Dashboard. For ...
  https://www.drugpatentwatch.com/p/drug-class/Catecholamine-depleting+Sympatholytic
*  Sympatholytic - Wikipedia
A sympatholytic (or sympathoplegic) drug is a medication that opposes the downstream effects of postganglionic nerve firing in ... Sympatholytics at the US National Library of Medicine Medical Subject Headings (MeSH). ... Sympathomimetic drug "Dorlands Medical Dictionary:sympatholytic". Brock, JA; Cunnane, TC (November 1988). "Studies on the mode ...
  https://en.wikipedia.org/wiki/Sympatholytic
*  Abstract 289: Effect of Central Sympatholytic Treatment on the Anti-Hypertensive Response of Renal Denervation in the...
These findings do not support the idea that patients taking effective doses of centrally acting sympatholytics will enhance the ... This study tested the hypothesis that pretreatment with a central sympatholytic would augment the response to renal denervation ... Abstract 289: Effect of Central Sympatholytic Treatment on the Anti-Hypertensive Response of Renal Denervation in the ... Abstract 289: Effect of Central Sympatholytic Treatment on the Anti-Hypertensive Response of Renal Denervation in the ...
  http://hyper.ahajournals.org/content/62/Suppl_1/A289
*  The Effect of 'Sympatholytic' Drugs on the Cardiovascular Responses to Epinephrine and Norepinephrine in Man (February ...
The Effect of 'Sympatholytic' Drugs on the Cardiovascular Responses to Epinephrine and Norepinephrine in Man ... The Effect of 'Sympatholytic' Drugs on the Cardiovascular Responses to Epinephrine and Norepinephrine in Man.' Circulation III ...
  https://profiles.nlm.nih.gov/ps/retrieve/ResourceMetadata/XFBBFJ
*  Sansert - Vasoconstrictor Agents, Serotonin Antagonists, Sympatholytics, ATC:N02CA04
Methysergide has been shown, in vitro and in vivo, to inhibit or block the effects of serotonin, a substance which may be involved in the mechanism of vascular headaches. Serotonin has been variously described as a central neurohumoral agent or chemical mediator, as a "headache substance" acting directly or indirectly to lower pain threshold, as an intrinsic "motor hormone" of the gastrointestinal tract, and as a "hormone" involved in connective tissue reparative processes ...
  http://pharmacycode.com/Sansert.html
*  Serten - Sympatholytics, Antihypertensive Agents, Antiarrhythmic Agents, Adrenergic Agents, ATC:C07AB03, ...
Atenolol, a competitive beta(1)-selective adrenergic antagonist, has the lowest lipid solubility of this drug class. Although it is similar to metoprolol, atenolol differs from pindolol and propranolol in that it does not have intrinsic sympathomimetic properties or membrane-stabilizing activity. Atenolol is used alone or with chlorthalidone in the management of hypertension and edema ...
  http://pharmacycode.com/Serten.html
*  Methergine and methylergonovine Drug Interactions - Drugs.com
The recommended maximum number of medicines in the 'sympatholytics' category to be taken concurrently is usually one. Your list ... includes two medicines belonging to the 'sympatholytics' category:. *methylergonovine (active ingredient in Methergine ( ...
  https://www.drugs.com/drug-interactions/methergine-with-methylergonovine-1605-974-1605-0.html
*  Adrenergic blocking agents | definition of adrenergic blocking agents by Medical dictionary
sympatholytic drugs. (redirected from adrenergic blocking agents). Also found in: Dictionary. sympatholytic drugs Drugs that ... a href='https://medical-dictionary.thefreedictionary.com/adrenergic+blocking+agents',sympatholytic drugs,/a,. *Facebook ...
  https://medical-dictionary.thefreedictionary.com/adrenergic+blocking+agents
*  Patent US5840334 - Self-binding shearform compositions - Google Patents
... sympatholytics; thyroid preparations; tranquilizers; uterine relaxants; vaginal preparations; vasoconstrictors; vertigo agents ...
  http://www.google.com/patents/US5840334?dq=6,205,432
*  Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients - Full Text View -...
The primary objective of this study is to assess QTc (an interval of the heart rhythm) interaction effects between lofexidine and methadone. The secondary objectives of the study are to evaluate the safety and tolerability of lofexidine by evaluating and monitoring pharmacokinetics (amounts of drug in the blood), vital signs (heart rate and blood pressure) and adverse events (side effects) when co-administered with methadone; to describe effects on opiate withdrawal when lofexidine is introduced following a 50% methadone dose reduction, as required to elicit a withdrawal response; and to evaluate the QTc interaction effects of lofexidine compared with placebo. The investigators hypothesize that while both agents (lofexidine and methadone) are known to prolong the QTc interval, the combination of the drugs will not create an additive effect which creates a significant safety concern. The investigators further hypothesize that subjects will be able to tolerate the therapeutic dose of lofexidine ...
  https://clinicaltrials.gov/ct2/show/NCT01650649?recr=Open&intr=methadone&rank=20
*  Coreg CR, Blood Vessel Stiffness and Blood Vessel Function - Full Text View - ClinicalTrials.gov
Sympatholytics. Adrenergic beta-1 Receptor Antagonists. Adrenergic beta-Antagonists. Adrenergic Antagonists. Adrenergic Agents ...
  https://clinicaltrials.gov/ct2/show/NCT00732511
*  BOAT: Beta Blocker Uptitration With OptiVol After Cardiac Resynchronization Therapy (CRT) - Full Text View - ClinicalTrials.gov
Sympatholytics. Autonomic Agents. Peripheral Nervous System Agents. Physiological Effects of Drugs. Adrenergic beta-1 Receptor ...
  https://clinicaltrials.gov/ct2/show/NCT00433043
*  Early Manifest Glaucoma Trial (EMGT) - Full Text View - ClinicalTrials.gov
Sympatholytics. Autonomic Agents. Peripheral Nervous System Agents. Physiological Effects of Drugs. Adrenergic beta-1 Receptor ...
  https://www.clinicaltrials.gov/ct2/show/NCT00000132
*  Food Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg to Lopressor HCT® Tablets 100/50 mg - Full Text View -...
Sympatholytics. Autonomic Agents. Peripheral Nervous System Agents. Adrenergic beta-1 Receptor Antagonists. Adrenergic beta- ...
  https://clinicaltrials.gov/ct2/show/NCT00649233
*  Lofexidine for Inpatient Opiate Detox - Full Text View - ClinicalTrials.gov
The main objective of this study is to investigate the effectiveness of lofexidine in reducing withdrawal symptoms among subjects undergoing opiate detoxification. Currently, lofexidine is the most commonly used non-opiate medication for detoxification from opiates in the United Kingdom (UK). There is no non-opiate medication approved by the Food and Drug Administration (FDA) for the same indication in the United States (US). The only medications currently approved by the FDA for opiate detoxification are methadone and buprenorphine. These medications, however, have the potential to be abused. Lofexidine, on the other hand, offers a unique advantage for opiate detoxification because it is not addicting, is easy to use, and has a favorable safety profile ...
  https://clinicaltrials.gov/ct2/show/NCT00235729